0.286 -0.007 (-2.36%) | 04-23 16:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 0.43 | 1-year : | 0.52 |
Resists | First : | 0.37 | Second : | 0.44 |
Pivot price | 0.3 | |||
Supports | First : | 0.25 | Second : | 0.21 |
MAs | MA(5) : | 0.27 | MA(20) : | 0.31 |
MA(100) : | 0.31 | MA(250) : | 1.26 | |
MACD | MACD : | -0.1 | Signal : | -0.1 |
%K %D | K(14,3) : | 21.1 | D(3) : | 15.2 |
RSI | RSI(14): 44.1 | |||
52-week | High : | 5.28 | Low : | 0.25 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ FOXO ] has closed above bottom band by 33.1%. Bollinger Bands are 0.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 0.3 - 0.3 | 0.3 - 0.3 |
Low: | 0.27 - 0.27 | 0.27 - 0.27 |
Close: | 0.28 - 0.29 | 0.29 - 0.29 |
FOXO Technologies Inc., a technology platform company, focuses on commercializing longevity science through products and services that serve the life insurance industry. The company is developing products and services that combine longevity science with life insurance to support the consumer health and wellness engagement, and to simplify the consumer underwriting journey. It offers FOXO Labs, a services platform that integrates saliva-based epigenetic biomarkers into accelerated underwriting protocols to improve the customer underwriting journey; and FOXO Life, an insurance products platform that offers proprietary life insurance products and third-party life insurance carrier products based on bundling longevity science with life insurance. The company was founded in 2019 and is based in Minneapolis, Minnesota.
Tue, 23 Apr 2024
FOXO Technologies Faces NYSE Compliance Challenge - TipRanks.com - TipRanks
Tue, 23 Apr 2024
FOXO Technologies Inc. Announces Receipt of Notice of Non-Compliance with NYSE Continued Listing Requirements - GlobeNewswire
Wed, 14 Feb 2024
FOXO Technologies Announces Non-Binding Agreement for Potentially Transformative Merger with M2i Global - GlobeNewswire
Wed, 14 Feb 2024
FOXO Technologies to merge with M2i Global By Investing.com - Investing.com
Thu, 08 Feb 2024
FOXO Technologies Strikes Key $5M Stock Deal with ClearThink - TipRanks.com - TipRanks
Thu, 25 Jan 2024
FOXO Technologies Announces Appointment of Capital Markets Veteran Francis Colt deWolf to the Board of Directors - Business Wire
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
AMEX
|
|
Sector:
Healthcare
|
|
Industry:
Medical - Healthcare Information Services
|
|
Shares Out | 0 (M) |
Shares Float | 6 (M) |
Held by Insiders | 2.89e+006 (%) |
Held by Institutions | 46 (%) |
Shares Short | 72 (K) |
Shares Short P.Month | 0 (K) |
EPS | -3.946e+007 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0 |
Profit Margin | 0 % |
Operating Margin | -41 % |
Return on Assets (ttm) | 433.3 % |
Return on Equity (ttm) | -93.5 % |
Qtrly Rev. Growth | 457000 % |
Gross Profit (p.s.) | -41.44 |
Sales Per Share | 0 |
EBITDA (p.s.) | 0 |
Qtrly Earnings Growth | -17.4 % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | -15 (M) |
PE Ratio | -0.01 |
PEG Ratio | 0 |
Price to Book value | 0 |
Price to Sales | 0 |
Price to Cash Flow | -0.32 |
Dividend | 0 |
Forward Dividend | 243680 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |